IBDEI1R9 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31395,1,3,0)
 ;;=3^Thyrotoxicosis,Unspec w/o Thyrotoxic Crisis/Storm
 ;;^UTILITY(U,$J,358.3,31395,1,4,0)
 ;;=4^E05.90
 ;;^UTILITY(U,$J,358.3,31395,2)
 ;;=^5002492
 ;;^UTILITY(U,$J,358.3,31396,0)
 ;;=E05.91^^190^1935^54
 ;;^UTILITY(U,$J,358.3,31396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31396,1,3,0)
 ;;=3^Thyrotoxicosis,Unspec w/ Thyrotoxic Crisis/Storm
 ;;^UTILITY(U,$J,358.3,31396,1,4,0)
 ;;=4^E05.91
 ;;^UTILITY(U,$J,358.3,31396,2)
 ;;=^5002493
 ;;^UTILITY(U,$J,358.3,31397,0)
 ;;=E89.0^^190^1935^47
 ;;^UTILITY(U,$J,358.3,31397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31397,1,3,0)
 ;;=3^Postprocedural Hypothyroidism
 ;;^UTILITY(U,$J,358.3,31397,1,4,0)
 ;;=4^E89.0
 ;;^UTILITY(U,$J,358.3,31397,2)
 ;;=^5003035
 ;;^UTILITY(U,$J,358.3,31398,0)
 ;;=E03.2^^190^1935^31
 ;;^UTILITY(U,$J,358.3,31398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31398,1,3,0)
 ;;=3^Hypothyroidism d/t Meds/Oth Exogenous Substances
 ;;^UTILITY(U,$J,358.3,31398,1,4,0)
 ;;=4^E03.2
 ;;^UTILITY(U,$J,358.3,31398,2)
 ;;=^5002471
 ;;^UTILITY(U,$J,358.3,31399,0)
 ;;=E03.9^^190^1935^32
 ;;^UTILITY(U,$J,358.3,31399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31399,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,31399,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,31399,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,31400,0)
 ;;=E06.0^^190^1935^50
 ;;^UTILITY(U,$J,358.3,31400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31400,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,31400,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,31400,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,31401,0)
 ;;=E06.1^^190^1935^51
 ;;^UTILITY(U,$J,358.3,31401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31401,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,31401,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,31401,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,31402,0)
 ;;=C73.^^190^1935^36
 ;;^UTILITY(U,$J,358.3,31402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31402,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,31402,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,31402,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,31403,0)
 ;;=E10.21^^190^1935^9
 ;;^UTILITY(U,$J,358.3,31403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31403,1,3,0)
 ;;=3^DM Type 1 w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,31403,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,31403,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,31404,0)
 ;;=E10.9^^190^1935^11
 ;;^UTILITY(U,$J,358.3,31404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31404,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,31404,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,31404,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,31405,0)
 ;;=E11.21^^190^1935^15
 ;;^UTILITY(U,$J,358.3,31405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31405,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,31405,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,31405,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,31406,0)
 ;;=E11.39^^190^1935^16
 ;;^UTILITY(U,$J,358.3,31406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31406,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,31406,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,31406,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,31407,0)
 ;;=E11.43^^190^1935^14
 ;;^UTILITY(U,$J,358.3,31407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31407,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,31407,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,31407,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,31408,0)
 ;;=E11.59^^190^1935^12
 ;;^UTILITY(U,$J,358.3,31408,1,0)
 ;;=^358.31IA^4^2
